{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:19:36Z","timestamp":1788725976495,"version":"build-2803163510"},"reference-count":44,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Taxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive data search was performed in PubMed, Web of Science, and Scopus up to August 2024. The studies that compare neuropathy in taxane agents were systematically reviewed. A network meta-analysis was carried out based on a Bayesian framework to evaluate the incidence of peripheral neuropathy in taxanes compared to paclitaxel, as reference comparator. The Surface Under the Cumulative Ranking Curve (SUCRA) was used to rank taxanes based on their neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 27 studies with 12101 patients were included. When compared with paclitaxel, nab-paclitaxel was associated with a significantly higher incidence of peripheral neuropathy (OR: 1.74, CrI: 1.22\u20132.48). Docetaxel (OR: 0.626, CrI: 0.441\u20130.881) and cabazitaxel (OR: 0.158, CrI: 0.0664\u20130.375) demonstrated a significantly lower incidence of peripheral neuropathy compared to paclitaxel. Liposomal paclitaxel and PICN lack significant difference compared to paclitaxel. Our analysis provided the order for peripheral neuropathy (from lowest to highest) as follows: cabazitaxel, docetaxel, liposomal paclitaxel, paclitaxel, PICN, nab-paclitaxel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nab-paclitaxel is associated with a significantly higher incidence of peripheral neuropathy compared to paclitaxel in females with BC. Docetaxel and cabazitaxel are linked with less peripheral neuropathy compared with paclitaxel in this population. No significant differences were observed in liposomal paclitaxel and PICN compared to paclitaxel.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251405216","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:29:36Z","timestamp":1765816176000},"page":"1153-1167","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-2105","authenticated-orcid":false,"given":"Samineh","family":"Beheshtirouy","sequence":"first","affiliation":[{"name":"Tabriz University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-1048","authenticated-orcid":false,"given":"Zeinab","family":"Nikniaz","sequence":"additional","affiliation":[{"name":"Tabriz University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-6039","authenticated-orcid":false,"given":"Saba","family":"Ghaffary","sequence":"additional","affiliation":[{"name":"Tessonics Medical Systems"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raha","family":"Jaberi","sequence":"additional","affiliation":[{"name":"Tabriz University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7931-4632","authenticated-orcid":false,"given":"Elnaz","family":"Shaseb","sequence":"additional","affiliation":[{"name":"Tabriz University of Medical Sciences"},{"name":"Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00285-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00168-y"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Kanbayashi Y Hosokawa T. Predictors of Chemotherapy-Induced Peripheral Neuropathy. 2012.","DOI":"10.5772\/27563"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14870-y"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.8.1041"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2607-5"},{"key":"e_1_3_3_8_2","first-page":"440","article-title":"Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer","volume":"37","author":"Nightingale G","year":"2012","unstructured":"Nightingale G, Ryu J. Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P t 2012; 37: 440\u2013448.","journal-title":"P t"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxics9100229"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.09.006"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00542-2"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.04.021"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.04.013"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.09.006"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","unstructured":"Kus T Aktas G Kalender M et al. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015; 24. 10.1007\/s00520-015-2898-z.","DOI":"10.1007\/s00520-015-2898-z"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0057"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0023"},{"key":"e_1_3_3_20_2","first-page":"18","article-title":"Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Liu M","year":"2021","unstructured":"Liu M, Liu S, Yang L, et al. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. BMC Cancer 2021; 21: 18.","journal-title":"BMC Cancer"},{"key":"e_1_3_3_21_2","first-page":"30","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis","volume":"10","author":"Lee H","year":"2020","unstructured":"Lee H, Park S, Kang JE, et al. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis. Sci Rep 2020; 10: 30.","journal-title":"Sci Rep"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.304"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.756393"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13982"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw290"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3786"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2174\/157015906776359568"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.15254"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1635-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.10.008"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5298"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.07.001"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01551-z"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0664"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4200-1"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05851-8"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4612"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.2079"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00542-2"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3202-5"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.92004"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2009.01235.x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.027"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9651-3"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30421"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251405216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251405216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251405216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:31:45Z","timestamp":1787650305000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251405216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251405216"],"URL":"https:\/\/doi.org\/10.1177\/10781552251405216","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}